Abstract
94 Maintenance of efficacy and safety with lebrikizumab up to one year of treatment in patients with moderate-to-severe atopic dermatitis with or without topical corticosteroids
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have